Skip to main content
. 2022 Dec 28;15(1):187. doi: 10.3390/cancers15010187

Figure 2.

Figure 2

(A,C) Progression-free survival (PFS) and (B,D) overall survival (OS) of patients classified according to (A,B) those undergoing or not undergoing surgery (OP) or radiotherapy (RT) for brain tumor or (C,D) those receiving different epidermal growth factor receptor tyrosine kinase inhibitors.